Home > PORTAL > about Us > Presentation >
Discover the services provided by SPIN’s website
How does www.spindermatology.org work?
The SPIN website offers you several services:
>> World Directory of Psoriasis Medial Resources
An interactive map listing dermatology centres specialised in the management of psoriasis. For each centre listed in this directory, you can see which medical resources they provide to psoriasis patients: available treatments, dedicated inpatient/outpatient facilities, interdisciplinary consultations, clinical trials, collaboration with patient associations.
For each centre, you can learn how to get an appointment, and you have access to the postal address and contact information.
>> World Directory of Atopic Dermatitis Medial Resources (coming soon!)
>> PIN News
Each member of the network can contribute with articles, events, works, etc., as long as the documents are provided in English. In this section, you will find:
- Our "Focus On" on major works or events of the network or special showcases of our partner medical groups or patient associations; also, you will find the latest news published in our website
- The news from the weboffice provides general information on SPIN activities
- In the events tab you will find a list of national and international events such as conferences, meetings, World Psoriasis Day...
- The news from medical groups showcasing the works shared by the national groups
- The news from patient associations presenting the latest activities of our partner associations
- The recent publications on psoriasis lists the latest Pumed articles on psoriasis and atopic dermatitis
When you wish to share information with the SPIN community, please send it in English to our weboffice. We will then post your news in the news section.
>> Running Projects
In this section you will find all the relevant information about SPIN’s ongoing projects and activities.
>> The Country Sites section
This section fosters the websites of national medical groups and of patient associations. Also, it allows those groups or associations that don’t have a website of their own, to create one for free. To proceed to the creation of your own website, please visit the "Country Sites" section and follow the instructions.
The national websites give you general information about the countries which are part of the network and it aims at:
- Fostering connections in each country between dermatologists and patients,
- Making easier to share information and to engage collaborations between countries.
To design and manage your own website, please use the website management tool.
>> The Website Management Tool
The website management tool is designed for your national medical group or for your patient association. This tool will guide you to build a website in your national language or to create a link with your pre-existent website. To use this section, you need to register. Please go to the website management tool at the bottom right of the homepage.
If you have any question, please, do no hesitate to contact our weboffice.
>> The International Links section
This section provides you links to other international psoriasis and atopic dermatitis organisations.
>> The Keywords section
This section gives you general information about psoriasis. It is a glossary with direct links to Pubmed’s main publications on psoriasis. A similar glossary for atopic dermatitis is to be developed soon.
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep..
2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)
see on pubmed
on Atopic Dermatitis
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
